Key facts
- This page summarizes Kleanthis G. Xanthopoulos's Form 4 filing for Zosano Pharma Corp.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2021, 20:35.
Kleanthis G. Xanthopoulos - 10 Jun 2021 Form 4 Insider Report for Zosano Pharma Corp
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 10 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Steven Lo, Attorney-in-Fact for Kleanthis G. Xanthopoulos
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Kleanthis G. Xanthopoulos filed Form 4 for Zosano Pharma Corp on 14 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZSAN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- +174%
- Price
- $0.000000
- Shares after
- 23,596
- Date
- 10 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZSAN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $0.9318
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units which vest in a single installment on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date.
Footnote F2
The option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date.